Medtronic (NYSE:MDT) Issues FY 2027 Earnings Guidance

Medtronic (NYSE:MDT) issued an update on its FY 2027 earnings guidance on Tuesday. The company provided EPS guidance of 5.940-6.000 for the period, compared to the consensus estimate of 5.950. The company issued revenue guidance of -. Medtronic also updated its Q2 2027 guidance to 1.320-1.340 EPS.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a research report on Monday, August 10th. Robert W. Baird decreased their price objective on shares of Medtronic from $93.00 to $85.00 and set a “neutral” rating for the company in a report on Thursday, June 4th. Rothschild & Co Redburn lowered their target price on shares of Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a research note on Friday, June 5th. Mizuho lowered their target price on shares of Medtronic from $120.00 to $100.00 and set an “outperform” rating for the company in a research note on Wednesday, June 3rd. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $118.00 target price on shares of Medtronic in a report on Thursday, June 4th. Eighteen research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $99.79.

Medtronic Stock Up 1.0%

NYSE:MDT traded up $0.90 on Tuesday, hitting $91.55. 4,504,376 shares of the company’s stock were exchanged, compared to its average volume of 8,802,534. The company has a market cap of $117.18 billion, a P/E ratio of 24.52, a price-to-earnings-growth ratio of 2.45 and a beta of 0.55. The firm has a 50-day moving average price of $85.81 and a 200-day moving average price of $85.48. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. Medtronic has a 52 week low of $73.31 and a 52 week high of $106.33.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. The business had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.Medtronic’s quarterly revenue was up 13.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, analysts expect that Medtronic will post 5.94 EPS for the current fiscal year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date is Friday, September 25th. Medtronic’s payout ratio is presently 77.21%.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 4,189 shares of Medtronic stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares of the company’s stock, valued at $2,994,539.88. This trade represents a 10.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.27% of the stock is currently owned by company insiders.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic raised its fiscal 2027 guidance, increasing organic revenue growth expectations to 7.25%–7.75% and diluted non-GAAP EPS guidance to $5.94–$6.00. The company cited broad-based demand and strength in newer growth platforms. Medtronic boosts fiscal 2027 forecasts on heart device demand
• Positive Sentiment: Fiscal first-quarter revenue rose 13.7% to $9.756 billion, exceeding the $9.55 billion analyst consensus. Adjusted EPS was $1.45 versus expectations of $1.39, while GAAP net income was $1.47 billion and GAAP EPS was $1.14. Medtronic Q1 Revenue Rises 13.7% to $9.756 Billion, Raises FY27 Guidance
• Positive Sentiment: All major businesses posted strong growth: Cardiovascular revenue increased 19.5%, Neuroscience 10.3%, Medical Surgical 10.0%, and Diabetes 16.9% on a reported basis. Cardiovascular demand was especially strong in complex procedures. Medtronic Lifts Outlook, Invests Over $700 Million in Heart Tech and Robotics
• Positive Sentiment: Medtronic is investing more than $700 million in heart technology and robotics, including a strategic investment in Pi-Cardia to advance complex transcatheter aortic valve replacement procedures. The spending could strengthen longer-term growth but may increase near-term investment costs. Medtronic Announces Strategic Investment in Pi-Cardia
• Neutral Sentiment: An additional fiscal week contributed approximately $570 million to first-quarter organic revenue, creating a comparison benefit investors will need to consider when assessing the underlying growth rate.
• Negative Sentiment: Recent insider activity was entirely selling, with three reported open-market sales and no purchases over the past six months. Institutional positioning was also mixed, with major investors both adding to and reducing their holdings.

Hedge Funds Weigh In On Medtronic

A number of institutional investors have recently bought and sold shares of MDT. Brighton Jones LLC increased its holdings in shares of Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after purchasing an additional 37,265 shares during the last quarter. Sivia Capital Partners LLC boosted its holdings in shares of Medtronic by 9.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after buying an additional 381 shares during the period. Jump Financial LLC acquired a new position in Medtronic in the 2nd quarter valued at about $299,000. Main Street Financial Solutions LLC raised its holdings in Medtronic by 28.9% in the 2nd quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company’s stock valued at $1,251,000 after acquiring an additional 3,218 shares during the period. Finally, HUB Investment Partners LLC lifted its position in Medtronic by 21.3% during the second quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company’s stock worth $1,676,000 after acquiring an additional 3,376 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).